España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Cubist Pharmaceuticals
ViroPharma and Other Biotech Stocks Recommended by Oppenheimer (VPHM)
Dendreon, Pharmacyclics and Other Biotech Takeover Targets
Watson Pharmaceuticals Earnings Preview
Dendreon, Pharmacyclics and Other Biotech Takeover Targets
Watson Pharmaceuticals Earnings Preview
Jefferies Increases Sales Guidance on Cubist Pharmaceuticals
Bank of America Reiterates Neutral and PT of $39 on Cubist Pharmaceuticals
Jefferies Increases Sales Guidance on Cubist Pharmaceuticals
Bank of America Reiterates Neutral and PT of $39 on Cubist Pharmaceuticals
UPDATE: Jefferies Raises PT on Cubist Pharmaceuticals
Jefferies Raises PT on Cubist Pharmaceuticals To $44
Read More...
Cubist Pharmaceuticals Recent News
Global Hunter Initiates Cubist Pharmaceuticals At Neutral
UPDATE: Oppenheimer Color On CBST Upgrade
Oppenheimer Upgrades Cubist Pharmaceuticals To Outperform, $37 PT
Oppenheimer Maintains Perform on Cubist Pharmaceuticals (CBST)
Jefferies Comments On Cubist Pharmaceuticals 1Q Sales
Lazard Upgrades Cubist Pharmaceuticals To Buy, $33 PT
Needham Raises PT On Cubist Pharmaceuticals To $33
Wedbush Raises PT On Cubist Pharmaceuticals To $32
CBST Sales Rev Guidance 3-6% Higher Than Jefferies' Estimate
Cubist Pharmaceuticals 3Q EPS Report
3Q Results For CBST Report On 10/14
